Please assess the completion status of the following clinical trial:

Trial Title: Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed CD20+ multiple myeloma~  * CD20+ disease defined as co-expression of CD20 on ≥ 25% of the clonal plasma cell population as defined by immunohistochemical or flow cytometric staining of a bone marrow or plasmacytoma specimen obtained at study entry~    * For flow cytometry, this is determined by calculating the frequency of CD20+ CD138+ double-positive cells within the total CD138+ plasma cell population~   * For immunohistochemistry, this is determined by dual staining for CD20 and the involved clonal light chain (kappa or lambda), with a determination of the percent double-positive (≤ 25% or ≥ 25%)~* Symptomatic multiple myeloma that has relapsed or progressed after at least 1 prior anti-myeloma therapeutic regimen~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Life expectancy \> 16 weeks (4 months)~* ANC ≥ 1,500/μL (unless low ANC due to multiple myeloma)~* Platelets ≥ 100,000/μL (unless low platelets are due to multiple myeloma)~* Serum bilirubin ≤ 2.0 mg/dL~* AST, ALT, and alkaline phosphatase \< 3 times upper limit of normal~* Serum creatinine ≤ 2.5 mg/dL~* Able to understand the investigational nature of lenalidomide and rituximab combination therapy and to give informed consent~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective double-method contraception at least 28 days before, during, and for at least 28 days after completion or discontinuation of study treatment~* Able to take acetylsalicylic acid (ASA) (325 mg) daily as prophylactic anticoagulation (patients intolerant to ASA may use warfarin or low molecular weight heparin)~* Prior malignancies with a disease free interval of ≥ 5 years allowed~* No history of thromboembolic disease within the past 6 months, regardless of anticoagulation~* No myocardial infarction within the past 6 months~* No New York Hospital Association class III or IV heart failure~* No uncontrolled angina~* No severe uncontrolled ventricular arrhythmias~* No active hepatitis B or C infection~* No HIV 1or 2 positivity~* No acute ischemia or active conduction system abnormalities as evidenced by ECG~* No history of hypersensitivity reactions to lenalidomide, thalidomide, or rituximab~* No other medical condition or laboratory evaluation that, in the treating physician's or principal investigators' opinion, makes the patient unsuitable to participate in this clinical trial~* No concurrent active malignancy other than nonmelanoma skin cancers or carcinoma-in-situ of the cervix~PRIOR CONCURRENT THERAPY:~* At least 3 weeks since prior therapy, including radiotherapy~* Prior lenalidomide or thalidomide allowed~* No prior rituximab

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Lenalidomide and Rituximab (Type: EXPERIMENTAL): This study will employ a Simon optimal two-stage design. Patients will receive lenalidomide 25 mg daily for days 1-21 of each 28 day cycle. Rituximab 375 mg/m2 will be given weekly for 4 weeks beginning 1 week after the start of lenalidomide therapy (weeks 2-5), and then once 8 weeks later (week 13). Patients with stable disease or better after 4 cycles (week 16, in the absence of delays for toxicity) will be able to continue on therapy on the same lenalidomide schedule and with rituximab 375 mg/m2 given once every 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).